Francesco de Rubertis
Chairman bij CENTESSA PHARMACEUTICALS PLC
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
David Grainger | M | 58 |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.
SDS Therapeutics Ltd.
SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK.
Critical Pressure Ltd.
Critical Pressure Ltd. Pharmaceuticals: MajorHealth Technology Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom. | 9 jaar |
Allen Cunningham | M | - |
Rivus Pharmaceuticals, Inc.
Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | - |
Rémy Henri Luthringer | M | 63 |
Orexia Therapeutics Ltd.
Orexia Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Orexia Ltd. develop orally administered orexin positive modulators for the treatment of neurological diseases. The company was founded on October 5, 2018 and is headquartered in London, the United Kingdom.
Inexia Ltd.
Inexia Ltd. Medical SpecialtiesHealth Technology Inexia Ltd. develops intranasal orexin positive modulators for the treatment of narcolepsy. The company is headquartered in London, the United Kingdom. | 10 jaar |
Geoff Race | M | 63 | 14 jaar | |
Fred Ahlholm | M | 58 | 10 jaar | |
Giovanni Mariggi | M | 39 |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | 12 jaar |
Kevin Johnson | M | 64 |
Index Ventures (UK) LLP
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | 14 jaar |
Michèle Ollier | M | 65 |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | 17 jaar |
Ypke van Oosterhout | M | 60 |
Xenikos BV
Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | 15 jaar |
Simon Westbrook | M | - |
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | 12 jaar |
Simon Lambden | M | - |
Critical Pressure Ltd.
Critical Pressure Ltd. Pharmaceuticals: MajorHealth Technology Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom. | - |
James Leiper | M | - |
Critical Pressure Ltd.
Critical Pressure Ltd. Pharmaceuticals: MajorHealth Technology Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom. | - |
Gregory Mark Weinhoff | M | 53 | 3 jaar | |
Giovanni Pericolini | M | - |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | 8 jaar |
James Edward Coleman | M | 49 |
UltraHuman Ltd.
UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | 9 jaar |
Samarth Kulkarni | M | 45 | 3 jaar | |
Jayson Dallas | M | 56 |
Rivus Pharmaceuticals, Inc.
Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | 3 jaar |
Kristen K. Sheppard | F | - | 2 jaar | |
Antoine Yver | M | 66 | 3 jaar | |
Mary Lynne Hedley | M | 61 | 3 jaar | |
Saurabh Saha | M | 47 | 3 jaar | |
Sarah Clare | F | - |
Synox Therapeutics Ltd.
Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | 3 jaar |
William James Jonathan Finlay | M | - |
UltraHuman Ltd.
UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | 9 jaar |
Nick la Thangue | M | - |
Synox Therapeutics Ltd.
Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | - |
Carol Stuckley | F | 68 | 3 jaar | |
David Kupfer | M | 84 | 9 jaar | |
Jan van Heek | M | 75 | 10 jaar | |
Brett Zbar | M | 51 | 3 jaar | |
Shaharyar Khan | M | - |
Rivus Pharmaceuticals, Inc.
Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | - |
Giuseppe Zocco | M | 58 |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | - |
Fouzia Laghrissi-Thodes | M | 61 | 9 jaar | |
Mario Alberto Accardi | M | 38 |
Inexia Ltd.
Inexia Ltd. Medical SpecialtiesHealth Technology Inexia Ltd. develops intranasal orexin positive modulators for the treatment of narcolepsy. The company is headquartered in London, the United Kingdom.
Orexia Therapeutics Ltd.
Orexia Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Orexia Ltd. develop orally administered orexin positive modulators for the treatment of neurological diseases. The company was founded on October 5, 2018 and is headquartered in London, the United Kingdom. | - |
Mathias Hukkelhoven | M | 70 | 2 jaar | |
Jemila Houacine | F | - |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | - |
Arjun Goyal | M | - | 3 jaar | |
Paul-Peter Tak | M | 64 |
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | 6 jaar |
Alasdair Thong | M | - |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | 8 jaar |
James Andrew Huntington | M | - |
SDS Therapeutics Ltd.
SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK. | - |
Marie Noëlle Venturi-Zen-Ruffinen | M | 49 |
University of Geneva
| 15 jaar |
Susan Gasser | M | 69 |
University of Geneva
| - |
Patrick Yue | M | - | 1 jaar | |
Yann Dean | M | - |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | - |
Jake Simson | M | 38 |
Xenikos BV
Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | - |
Benjamin Perry | M | - |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | 2 jaar |
Michael Davidson | M | 74 | 8 jaar | |
Shyam Masrani | M | 34 |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | - |
Thibaud Portal | M | - |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | - |
Nicholas Williams | M | - |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | - |
David Chao | M | 56 | 3 jaar | |
Christine Janet Martin | F | 55 |
SDS Therapeutics Ltd.
SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK. | - |
CARL KILANDER | M | - |
Synox Therapeutics Ltd.
Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | - |
Michaël Vlemmix | M | - |
Synox Therapeutics Ltd.
Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | - |
Grégoire Carasso | M | 43 |
University of Geneva
| 11 jaar |
Paul Sekhri | M | 66 |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | 4 jaar |
Karen Anderson | F | 57 | 2 jaar | |
Tom Roy | M | - |
Hamilton Pharmaceuticals, Inc.
Hamilton Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Hamilton Pharmaceuticals, Inc. develops and supplies pharmaceuticals. It also develops and commercializes novel medical treatments for central nervous system disease. The company was founded in April 2004 and is headquartered in Washington, DC. | 19 jaar |
Frank Kung | M | 75 |
Hamilton Pharmaceuticals, Inc.
Hamilton Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Hamilton Pharmaceuticals, Inc. develops and supplies pharmaceuticals. It also develops and commercializes novel medical treatments for central nervous system disease. The company was founded in April 2004 and is headquartered in Washington, DC. | - |
Raj Bhikhu Parekh | M | 63 |
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | 10 jaar |
Ton Logtenberg | M | 65 |
Synox Therapeutics Ltd.
Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | 3 jaar |
Bob Flanagan Flanagan | M | 67 |
Hamilton Pharmaceuticals, Inc.
Hamilton Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Hamilton Pharmaceuticals, Inc. develops and supplies pharmaceuticals. It also develops and commercializes novel medical treatments for central nervous system disease. The company was founded in April 2004 and is headquartered in Washington, DC. | - |
Douglas Williams | M | 66 |
Xenikos BV
Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | - |
Rajna Gibson Brandon | M | 61 |
University of Geneva
| - |
Jan Hammer | M | 47 |
Index Ventures (UK) LLP
| 14 jaar |
Ron D. Appel | M | - |
University of Geneva
| - |
Amos Bairoch | M | - |
University of Geneva
| - |
Arthur Franken | M | - |
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | 10 jaar |
Dirk Kersten | M | 49 |
Synox Therapeutics Ltd.
Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | - |
Maarten Frijlink | M | - |
Xenikos BV
Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | 9 jaar |
Emiliangelo Ratti | M | - |
Inexia Ltd.
Inexia Ltd. Medical SpecialtiesHealth Technology Inexia Ltd. develops intranasal orexin positive modulators for the treatment of narcolepsy. The company is headquartered in London, the United Kingdom. | - |
Eliot Forster | M | 58 |
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | 1 jaar |
Ion Stancu | M | 74 |
University of Geneva
| 19 jaar |
Joseph Reilly | M | 49 | 10 jaar | |
Christian Lovis | M | - |
University of Geneva
| - |
Peter Mollerup | M | - |
Egalet A/S
Egalet A/S Pharmaceuticals: MajorHealth Technology Egalet A/S operates as a specialty pharmaceuticals company. It develops opioid formulations for pain management based on abuse deterrent prolonged release erosion matrix technology in Denmark. The company develops prolonged and delayed release therapeutics for chronic pain management, including Parvulet, a delivery platform for facilitating dispensing of oral doses to pediatric and geriatric patient segments; and Egalet morphine. The company was founded by Jan Quistgaard in 1995 and is headquartered in Vaerloese, Denmark. | - |
Paul-Henri Lambert | M | 85 |
University of Geneva
| - |
Daphne Bavelier | M | - |
University of Geneva
| - |
Nicolas Gisin | M | 72 |
University of Geneva
| - |
Isabelle Romy | M | 59 |
University of Geneva
| - |
Martin Mignot | M | 40 |
Index Ventures (UK) LLP
| 14 jaar |
Jean-Pierre Danthine | M | 74 |
University of Geneva
| - |
Richard Treagus | M | 58 |
Hamilton Pharmaceuticals, Inc.
Hamilton Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Hamilton Pharmaceuticals, Inc. develops and supplies pharmaceuticals. It also develops and commercializes novel medical treatments for central nervous system disease. The company was founded in April 2004 and is headquartered in Washington, DC. | 11 jaar |
Christine Martin | M | - |
SDS Therapeutics Ltd.
SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK. | 4 jaar |
Daniel H. Rimer | M | 54 |
Index Ventures (UK) LLP
| 22 jaar |
Henry Peter | M | 67 |
University of Geneva
| 27 jaar |
Larry Glass | M | - |
Hamilton Pharmaceuticals, Inc.
Hamilton Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Hamilton Pharmaceuticals, Inc. develops and supplies pharmaceuticals. It also develops and commercializes novel medical treatments for central nervous system disease. The company was founded in April 2004 and is headquartered in Washington, DC. | 20 jaar |
Raymond Barlow | M | 55 |
Synox Therapeutics Ltd.
Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | 3 jaar |
Afksendyios Kalangos | M | - |
University of Geneva
| - |
Barbara Dalton | F | - |
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Jay Shepard | M | 66 |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | - |
Rogério Vivaldi Coelho | M | 60 | 7 jaar | |
Srini Akkaraju Akkaraju | M | 56 |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | - |
Francesco Sinigaglia | M | 71 |
BioXell SpA
BioXell SpA BiotechnologyHealth Technology BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy. | 10 jaar |
Joshua Brumm | M | 46 |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | 4 jaar |
Aaron Kantoff | M | 29 |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | 2 jaar |
John Varian | M | 64 |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | 4 jaar |
Kevin Haas | M | 59 |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | 4 jaar |
Marco Bottani | M | 78 |
BioXell SpA
BioXell SpA BiotechnologyHealth Technology BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy. | 3 jaar |
Michael Dybbs | M | 49 |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | 1 jaar |
William B. Boni | M | - | 6 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 47 | 47.47% |
Verenigde Staten | 25 | 25.25% |
Zwitserland | 15 | 15.15% |
Ierland | 7 | 7.07% |
Nederland | 4 | 4.04% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Francesco de Rubertis
- Persoonlijk netwerk